CCM
IOVA icon

Cutter Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Cutter Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-876,009
Closed -$8.23M – 32
2024
Q3 		$8.23M Buy
+876,009
New +$8.3M 2.43% 19
2024
Q1 		– Sell
-677,350
Closed -$5.51M – 31
2023
Q4 		$5.51M Buy
+677,350
New +$3.54M 2.63% 19

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Cutter Capital Management's IOVA Position: Q4 2024 in Review

Cutter Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 876,009 shares — an estimated $8.23M sold.

Cutter Capital Management first reported a position in IOVA in Q4 2023 and held it in 2 quarters. The position peaked at $8.23M in Q3 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Cutter Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Cutter Capital Management sold 876,009 Iovance Biotherapeutics shares in Q4 2024, an estimated $8.23M.
  • Cutter Capital Management first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 2 quarters.
  • Cutter Capital Management's Iovance Biotherapeutics position peaked at $8.23M in Q3 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Cutter Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.